Organic light-emitting diode and method of manufacturing the same
    11.
    发明申请
    Organic light-emitting diode and method of manufacturing the same 有权
    有机发光二极管及其制造方法

    公开(公告)号:US20050280361A1

    公开(公告)日:2005-12-22

    申请号:US11155562

    申请日:2005-06-20

    IPC分类号: H01L51/56 H05B33/00

    CPC分类号: H01L51/56 H01L2251/562

    摘要: An organic light-emitting diode (OLED) with an increased service life and a method of manufacturing the same are provided. The OLED is subjected to electromagnetic radiation with a spectrum that at least partially overlaps the absorption spectrum of an organic material layer of the OLED. As a result, the OLED has a longer service life, reduced decay in its initial brightness, and more saturated color than a conventional OLED.

    摘要翻译: 提供了具有更长使用寿命的有机发光二极管(OLED)及其制造方法。 对OLED进行电磁辐射,其光谱至少部分地与OLED的有机材料层的吸收光谱重叠。 结果,OLED比常规OLED具有更长的使用寿命,降低其初始亮度衰减和更饱和的颜色。

    Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
    12.
    发明授权
    Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof 失效
    四唑衍生物及其代谢相关病症的治疗方法

    公开(公告)号:US08637555B2

    公开(公告)日:2014-01-28

    申请号:US10535345

    申请日:2004-10-29

    IPC分类号: A61K31/407 C07D231/54

    摘要: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

    摘要翻译: 本发明涉及式(I)的某些四唑衍生物及其药学上可接受的盐,其表现出有用的药理学性质,例如作为RUP25受体的激动剂。 本发明还提供含有本发明化合物的药物组合物,以及使用本发明化合物和组合物治疗代谢相关疾病包括血脂异常,动脉粥样硬化,冠心病,胰岛素抵抗,2型糖尿病 ,综合征-X等。 此外,本发明还提供本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类,醛糖还原酶抑制剂,双胍类,HMG-CoA还原酶抑制剂,角鲨烯合成 抑制剂,贝特类,LDL分解代谢增强剂,血管紧张素转换酶(ACE)抑制剂,胰岛素分泌增强剂等。

    Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
    18.
    发明申请
    Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof 失效
    四唑衍生物及其代谢相关病症的治疗方法

    公开(公告)号:US20060217562A1

    公开(公告)日:2006-09-28

    申请号:US10535345

    申请日:2004-10-29

    IPC分类号: A61K31/416 C07D403/02

    摘要: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

    摘要翻译: 本发明涉及式(I)的某些四唑衍生物及其药学上可接受的盐,其表现出有用的药理学性质,例如作为RUP25受体的激动剂。 本发明还提供含有本发明化合物的药物组合物,以及使用本发明化合物和组合物治疗代谢相关疾病包括血脂异常,动脉粥样硬化,冠心病,胰岛素抵抗,2型糖尿病的方法 ,综合征-X等。 此外,本发明还提供本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类,醛糖还原酶抑制剂,双胍类,HMG-CoA还原酶抑制剂,角鲨烯合成 抑制剂,贝特类,LDL分解代谢增强剂,血管紧张素转换酶(ACE)抑制剂,胰岛素分泌增强剂等。